Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

Fig. 4

Biomarker models for prediction of prostate cancer aggressiveness. Receiver-operating characteristic curve (ROC) analysis as assessed according to low-risk ISUP GG (group I and II) and high-risk ISUP GG (group III, IV and V). a Total PSA, b Clinical panel (Age, T-classification, total PSA), c Biomarker panel (sTWEAK in semen, glucose levels in serum and mRNA levels of Fn14, KLK2, CXCR2 and CCR3 in semen cell sediment), d Biomarker panel in combination with total PSA

Back to article page